| Name | Title | Contact Details |
|---|
Miller Engineerings design and consulting team provides over 100 cumulative years of construction and design experience, which will ensure the success of your project.
We partner with you to identify, develop, and equip the leaders that will take your business further. Having worked with over 600 organizations from 30 nations around the world, we are trusted consultants to Fortune 50 companies and startups alike. We blend over 20 years of insight, honed while transforming parent company Barry-Wehmiller into a thriving $3.5B people-centric organization. Chapman & Co. partners with you by listening to your specific needs in order to deliver a tailored and holistic solution or off the shelf turnkey products for your organization. An organization isnt just a workplace, its where individuals spend the most of their daily life. We believe the greatest opportunity for good in this world lies within the organizations we interact with every day, and it begins with their leaders. To learn more about Chapman & Co. or how to partner with us, visit www.ccoleadership.com
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.